Simply through the viable cell (trypan blue exclusive) counting assay, our results showed that the DNA-PKcs inhibitors remarkably inhibited 786-0 RCC cell proliferation (Fig. 2A). This evidence concerns the gene PRKDC and renal cell carcinoma.